Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms

Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Prostate Cancer Survival Statistics. Cancer Research UK Web site. www.info.cancerresearchuk.org/cancerstats/types/prostate/survival/prostate-cancer-survival-statistics. Halabi, 2003, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 21, 1232, 10.1200/JCO.2003.06.100 Smaletz, 2002, Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration, J Clin Oncol, 20, 3972, 10.1200/JCO.2002.11.021 Armstrong, 2007, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis, Clin Cancer Res, 13, 6396, 10.1158/1078-0432.CCR-07-1036 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 De Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. In press. http://dx.doi.org/10.3410/f.717968072.793467743. De Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Parker, 2012, Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA) [abstract LBA4512], J Clin Oncol, 30 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Vickers, 2011, Prediction models: revolutionary in principle, but do they do more good than harm?, J Clin Oncol, 29, 2951, 10.1200/JCO.2011.36.1329 Scher, 2011, J Clin Oncol, 29 Schelman, 2011, First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc) [abstract 3102], J Clin Oncol, 29 Carden, 2008, Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer [abstract 5168], J Clin Oncol, 26 Jaime, 2012, Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging [abstract 2530], J Clin Oncol., 30 Wagner, 2011, A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors [abstract 3020], J Clin Oncol, 29 Yap, 2011, First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors, J Clin Oncol, 29, 4688, 10.1200/JCO.2011.35.5263 Molife, 2010, A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors [abstract 2599], J Clin Oncol, 28 Tan, 2010, First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma [abstract 3006], J Clin Oncol, 28 Smith, 2012, Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE) [abstract 4513], J Clin Oncol, 30 Molife R, de Bono JS, Bell S, Lumsden G, Temple G. A phase II trial to compare BIBF 1120 or BIBW 2992 monotherapy versus a combination of sequential administration of both medications in patients with hormone refractory prostate cancer (HRPC). Poster presented at: ASCO Genitourinary Cancers Symposium; February 2009; Orlando, FL, USA. Reid, 2010, Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate, J Clin Oncol, 28, 1489, 10.1200/JCO.2009.24.6819 Attard, 2009, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer, J Clin Oncol, 27, 3742, 10.1200/JCO.2008.20.0642 Danila, 2010, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer, J Clin Oncol, 28, 1496, 10.1200/JCO.2009.25.9259 Molife, 2010, Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC), Ann Oncol, 21, 109, 10.1093/annonc/mdp270 Tolcher, 2012, A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer, Ann Oncol, 23, 968, 10.1093/annonc/mdr353 Fizazi, 2012, Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer, Eur J Cancer, 48, 85, 10.1016/j.ejca.2011.10.014 Pienta, 2013, Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer, Invest New Drugs, 31, 760, 10.1007/s10637-012-9869-8 De Bono, 2007, Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer, J Clin Oncol, 25, 257, 10.1200/JCO.2006.07.0888 De Bono, 2012, Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy, Ann Oncol, 23, 1241, 10.1093/annonc/mdr380